1.25Open1.25Pre Close0 Volume10 Open Interest1.50Strike Price0.00Turnover0.00%IV-21.36%PremiumOct 18, 2024Expiry Date1.29Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.17Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Gritstone Bio Stock Discussion
this stock needs a reverse split ASAP
Gritstone bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer! Well tolerated with no advers events
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
Gritstone bio announced encouraging interim Phase 2 data for GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).
The study showed a 21% relative risk reduction of progression or death with GRANITE vs. control in all treated...
spike and down again, volume slowly building up
No comment yet